A modelling study released in March gives a clue at which price the jab, lenacapavir, would be worth the health department’s while
In December, the Global Fund and the US President’s Emergency Plan for Aids Relief committed to funding the roll-out of lenacapavir in countries they support
Gray is the first female president and chief executive of the council and served as the chairperson of the research committee on Covid-19
The Covid-19 pandemic has shown that vaccine development and testing timelines can be shrunk from decades to months, but not without shortcomings
Only some study participants have access to the tablet that can cut the risk of HIV infection by more than 90%.
If it works, the world’s latest HIV vaccine candidate may make it to market quicker than we think – and become a routine childhood vaccination
Jane Mahlangu is set to become one of the first 100 people in South Africa to receive an experimental jab that could prevent HIV – and make history
Recently the first participants in the HVTN 702 study received jabs of a vaccine that could stop HIV in its tracks
One tiny protein may hold the secret to ending the HIV pandemic.
A study conducted among almost 200 South African children is the largest of its kind.
We know more than ever about how to prevent HIV infection, including what may someday lead to the world’s first HIV vaccine.
The time for an HIV vaccine is now
We are not there yet, but experts are optimistic about a jab to prevent HIV coming to market in the near future.
If the progress we see today is anything to go by, it means we are closer than ever to having an HIV vaccine.
Three SARChI Research Chairs are focusing on the holy grail of HIV vaccine development to develop a therapeutic vaccine against the virus.
Why would young, single African women not take free drugs that could potentially save them from contracting a life-threatening infection?
Access to antiretrovirals has increased tenfold,
but efforts aimed at prevention must be renewed.
No image available
/ 28 November 2008
Clinical testing of the first HIV vaccine developed in Africa will start in the US next week, the SA Aids Vaccine Initiative said on Friday.
No image available
/ 19 October 2008
A year after a setback in the hunt for an HIV/Aids vaccine, researchers say their defeats have forced them to look for new ways of creating a defence.